XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.

J, Feliu; A, Salud; P, Escudero; L, Lopez-Gómez; M, Bolaños; A, Galán; JM, Vicent; A, Yubero; F, Losa; Castro J, De; Mon MA, de; E, Casado; M, González-Barón

doi:10.1038/sj.bjc.6603047

Public

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.

Shared by NobleBlocks on Apr 1, 2006 • 12:00 AM UTC

Authors:

Feliu J

Salud A

Escudero P

Abstract

The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged > or = 70 years received oxaliplatin 130 mg m(-2) ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!